Wellington Management Group LLP Sells 3,111 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Wellington Management Group LLP reduced its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 7.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,550 shares of the company’s stock after selling 3,111 shares during the quarter. Wellington Management Group LLP’s holdings in Dyne Therapeutics were worth $908,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. KBC Group NV increased its position in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after purchasing an additional 978 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Dyne Therapeutics in the fourth quarter worth approximately $257,000. Magnetar Financial LLC bought a new position in Dyne Therapeutics during the fourth quarter valued at approximately $263,000. E Fund Management Co. Ltd. raised its stake in shares of Dyne Therapeutics by 11.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock worth $279,000 after acquiring an additional 1,249 shares in the last quarter. Finally, Legato Capital Management LLC bought a new stake in shares of Dyne Therapeutics in the 4th quarter worth approximately $305,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $7.04 on Monday. The firm’s 50-day moving average price is $11.86 and its 200-day moving average price is $21.24. The company has a market capitalization of $796.37 million, a PE ratio of -1.98 and a beta of 1.21. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. Equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 6,237 shares of company stock valued at $77,760. 20.77% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on DYN shares. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Scotiabank assumed coverage on Dyne Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price for the company. HC Wainwright restated a “buy” rating and set a $46.00 target price on shares of Dyne Therapeutics in a report on Monday, March 17th. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday, March 17th. Finally, JPMorgan Chase & Co. dropped their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $47.46.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.